Background Only clinically validated HPV assays can be accepted in cervical cancer
screening. Objectives To update the list of high-risk HPV assays that fulfil the 2009 …

Several countries are in the process of switching to high-risk human papillomavirus (hrHPV)
testing for cervical cancer screening. Given the multitude of available tests, validated assays …

Background Deep learning has presented considerable potential and is gaining more
importance in computer assisted diagnosis. As the gold standard for pathologically …

Background Type-specific high-risk HPV (hrHPV) infection is related to cervical
carcinogenesis. The prevalence of hrHPV infection varies geographically, which might …

With more than 200 types identified, human papillomavirus (HPV) commonly causes
infections of the skin and mucosa. HPV infection is the most common sexually transmitted …

Abstract Background The VALidation of HPV GENoyping Tests (VALGENT) is an
international initiative designed to validate HPV assays with genotyping capability. The …

Mucosal infection by the human papillomavirus (HPV) is responsible for a growing number
of malignancies, predominantly represented by cervical cancer and oropharyngeal …

Objectives Human papillomavirus (HPV) assays are increasingly used for primary cervical
screening and HPV-vaccination-effect monitoring. We undertook a systematic literature …

Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent
disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an …

This study describes a validation of the BD Onclarity HPV (Onclarity) assay using the
international guidelines for HPV test requirements for cervical cancer screening of women …